Passage Bio doses first subject in Phase I/II dementia gene trial
Analysing the safety and tolerability of PBFT02 is the primary endpoint of the trial.
Central Nervous System
Latest in
Central Nervous System
Odyssey reports positive data from Phase I concussion trial
According to the safety findings, PRV-002 was found to be safe and well tolerated in this cohort.
Findings suggest urban-rural divide in early-onset dementia diagnosis
The geographic disparities behind early-onset dementia highlight the need to bridge the urban-rural divide.
By
Oligomerix receives NIH grant for Phase Ia Alzheimer’s disease study
The trial will analyse the safety, tolerability and pharmacokinetics of various doses of OLX-07010 in healthy elderly subjects.
Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
By
Karuna reports positive Phase III KarXT data in schizophrenia
KarXT offered a statistically significant and clinically meaningful 9.6-point decline in the PANSS total score versus placebo.
Pipeline Moves: Phase II gout trial termination slashes advancement prospects
We also review assets in allergic rhinitis, anorexia, paroxysmal nocturnal haemoglobinuria, and polyomavirus infections.
By
Physicians highlight need for improved treatments targeting key symptoms of ASD
Most currently approved ASD therapies are prescribed off-label, resulting in significant opportunity for developers in the market.
By